Submission of newspaper publication w.r.t un-audited financial statements for the quarter ended 30.06.2025
Awaiting price reaction for this filing.
MPS Pharmaa Limited (formerly Advik Laboratories) has submitted newspaper clippings of its unaudited financial results for the quarter ended 30 June 2025, published in Financial Express and Jansatta on 13 August 2025. On a standalone basis, the company reported a net loss of ₹22.01 lakhs, slightly better than the ₹22.24 lakh loss in Q1 FY25, while revenue from operations collapsed sharply from ₹4.77 lakhs to just ₹0.40 lakhs year-on-year. On a consolidated basis, the company swung to a net profit of ₹2,578.59 lakhs compared to a loss of ₹2,644.58 lakhs in the year-ago quarter, though consolidated revenue fell to ₹1,228.39 lakhs from ₹3,964.83 lakhs. The company carries negative other equity of ₹(1,803.07) lakhs, indicating accumulated losses have wiped out shareholder reserves on a standalone basis. The filing also reflects the company's recent name change from Advik Laboratories Limited to MPS Pharmaa Limited.
Mixed picture for shareholders: the standalone business is virtually non-operational with negligible revenue and persistent losses, while the consolidated turnaround to profit appears driven by subsidiary/other entity contributions. Negative standalone net worth remains a structural concern, though the consolidated profitability may support the stock in the near term.